Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3).
Recently, there has been increased interest in extending the provision for waivers of in vivo bioavailability and bioequivalence (BA-BE) studies that appeared in the guidance published by the Food and Drug Administration (FDA) (1) to pharmaceutical products containing Class 3 drugs (High solubility-Low Permeability). The extension of the Biopharmaceutics Classification System (BCS) to Class 3 drugs is meritorious because of its impact on public health policy considerations. The rate limiting step in the absorption of Class 3 drugs is the permeability through the intestinal membrane. This commentary will focus its attention on the scientific considerations which need to be examined to assess the risk and the benefit prior to granting a waiver of in vivo bioavailability and/or bioequivalence studies for Class 3 drugs. It will examine the forces affecting the interconnectivity of the neuronal, immunological and hormonal systems in the gastrointestinal tract that may affect its permeability and functionality. It will also challenge the assumption that in vitro dissolution and in vitro permeability studies in tissue cultures in the presence and absence of excipients are good predictors for in vivo dissolution and in vivo permeability which are at the heart of the BCS.
Stavchansky
Salomon
S
Division of Pharmaceutics, The University of Texas at Austin, College of Pharmacy, PHR 4.214C, Austin, Texas, 78712-1074, USA. Stavchansky@mail.utexas.edu
D000818:Animals; D001682:Biological Availability; D035843:Biomedical Research / Q000379:methods; D017277:Drug Approval / Q000331:legislation & jurisprudence; D016568:Drugs, Generic / Q000737:chemistry / Q000493:pharmacokinetics*; D006801:Humans; D010539:Permeability; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration
D016568:Drugs, Generic